 |
 |
 |
   
|
FACULTY DIRECTORY |
|
MPH, 2002,
University of Rochester
PhD, 2000, Neurophysiology/Biophysics, University of Rochester
BS, 1995, Medical Optics, Middlebury College, VT/Saratov State University, Russia
|
Katia Noyes, PhD, MPH
Associate Professor
Division of Health Services Research,
Community & Preventive Medicine
Contact Information:
University of Rochester
Community & Preventive Medicine
601 Elmwood Avenue, Box 644
Rochester, NY 14642
Office: 4-W317
Phone: (585) 275-8467
Fax: (585) 461-4532
Email: katia_noyes@urmc.rochester.edu
Research:
Research interests include cost-effectiveness studies in medicine and health,
health services utilization in geriatric illness, quality of life assessment,
medical decision-making, and analysis of clinical trials.
Curriculum Vitae |
|
OVERVIEW
|
| Dr. Noyes joined the Department of Community and Preventive Medicine at the URMC in 2000 as a postdoctoral research fellow to pursue training in cost-effectiveness and health services research. As a basic scientist in the biomedical field, Dr. Noyes came to realize the important role of various, non-biological factors, in determining people's health status.
Dr. Noyes is presently focusing on analysis of clinical and economic outcomes in elderly patients,
in particular, those with Parkinson's disease, depression, and subjects who received implantable cardiac defibrillators.
For her research, Dr. Noyes uses data from clinical trials as well as government health care surveys
and medical claims submitted to insurance. She is also interested in developing multivariate methods for
reducing uncertainty in cost-effectiveness studies that originates from missing data and population variance.
Dr. Noyes is involved in teaching graduate and medical curriculum courses on Cost-Effectiveness Research,
Quality of Care and Risk Adjustment, and Health Economics.
|
|
RECENT PUBLICATIONS
|
-
O'Connor AB, Noyes K, Holloway RG. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.
J Am Geriatr Soc. 2007 Aug;55(8):1176-84. Review.
- Huang DT, Sesselberg HW, McNitt S, Noyes K, Andrews ML, Hall WJ, Dick A, Daubert JP, Zareba W, Moss AJ; MADIT-II Research Group. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy.
J Cardiovasc Electrophysiol. 2007 Aug;18(8):833-8. Epub 2007 May 30.
- Noyes K, Dick AW, Holloway RG. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation.
Med Decis Making. 2007 May-Jun;27(3):327-34. Epub 2007 May 14.
- Dorsey ER, Thompson JP, Noyes K, Dick AW, Holloway RG, Schwid SR. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
Neurology. 2007 May 1;68(18):1524-8.
- Noyes K, Corona E, Zwanziger J, Hall WJ, Zhao H, Wang H, Moss AJ, Dick AW; Multicenter Automatic Defibrillator Implantation Trial II. Health-related quality of life consequences of implantable cardioverter defibrillators: results from MADIT II.
Med Care. 2007 May;45(5):377-85.
- Piotrowicz K, Noyes K, Lyness JM, McNitt S, Andrews ML, Dick A, Hall WJ, Moss AJ, Zareba W. Physical functioning and mental well-being in association with health outcome in patients enrolled in the Multicenter Automatic Defibrillator Implantation Trial II.
Eur Heart J. 2007 Mar;28(5):601-7. Epub 2007 Feb 12.
- Noyes K, Liu H, Holloway R, Dick AW. Accuracy of Medicare claims data in identifying Parkinsonism cases: comparison with the Medicare current beneficiary survey.
Mov Disord. 2007 Mar 15;22(4):509-14.
- Noyes K, Liu H, Temkin-Greener H. Cost of caring for Medicare beneficiaries with Parkinson's disease: impact of the CMS-HCC risk-adjustment model.
Dis Manag. 2006 Dec;9(6):339-48.
- Noyes K, Liu H, Holloway RG. What is the risk of developing parkinsonism following neuroleptic use?
Neurology. 2006 Mar 28;66(6):941-3.
- Noyes K, Dick AW, Holloway RG; Parkinson Study Group. Pramipexole versus levodopa in patients with early Parkinson's disease: effect on generic and disease-specific quality of life.
Value Health. 2006 Jan-Feb;9(1):28-38.
- Noyes K, Dick AW, Holloway RG; Parkinson Study Group. Pramipexole and levodopa in early Parkinson's disease: dynamic changes in cost effectiveness.
Pharmacoeconomics. 2005;23(12):1257-70.
- Noyes K, Liu H, Li Y, Holloway R, Dick AW. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries.
Mov Disord. 2006 Mar;21(3):362-72.
- Noyes K, Holloway RG. Evidence from cost-effectiveness research.
NeuroRx. 2004 Jul;1(3):348-55. Review.
- Noyes K, Dick AW, Holloway RG; Parkinson Study Group. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial.
Med Decis Making. 2004 Sep-Oct;24(5):472-85.
- Holloway R, Nesbit K, Bordley D, Noyes K. Teaching and evaluating first and second year medical students' practice of evidence-based medicine.
Med Educ. 2004 Aug;38(8):868-78.
|
|
